Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01386606 · ClinicalTrials.gov registry record · Phase 2
The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01386606 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT01386606, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The study will determine the effects of three doses of Androxal(enclomiphene citrate)on morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone (\<350 ng/dL)after 6 weeks of continuous dosing.
Interventions
- DRUG Testosterone
- DRUG Androxal (enclomiphene citrate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01386606
The ClinicalTrials.gov registry entry for NCT01386606 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Testosterone is the first listed.
NCT01386606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01386606 about?
NCT01386606 is a clinical study titled "The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)". The study will determine the effects of three doses of Androxal(enclomiphene citrate)on morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone (\<350 ng/dL)after 6 weeks of continuous dosing.
What is the current status of trial NCT01386606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01386606?
The interventions under investigation include: Testosterone (DRUG), Androxal (enclomiphene citrate) (DRUG).
Who is sponsoring clinical trial NCT01386606?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.